Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronic Anticoagulation in End-stage Renal Disease Patients
NCT05410275Phase 3Recruiting
- Sponsor
- University Hospital Tours
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rivaroxaban in Atrial fibrillation (AFib), sponsored by University Hospital Tours. Primary endpoints: Pharmacodynamics at 1 month and Pharmacokinetics at 1 month. Started Jan 2025; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05410275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05410275.